Artificial Intelligence
Guerbet: 2020 Half-year results
2020 half-year results
- Revenue affected by the COVID crisis
- -9.2% at current exchange rates at €363.7 million
- -8.4% at constant exchange rates (CER)1 at €367.1 million
- Satisfactory results in the midst of COVID
- Strict management of operating costs
- EBITDA margin rate of 14.7% of revenue
- Operating income of €25.4 million
- Net income of €8.2 million
- Improvement of the already very solid financial structure
- Sharp improvement in WCR
- Cash flow generation increase
- Net debt decrease
- Continued transformation of the Group
- Development strategy roadmap maintained: diagnostic imaging, interventional imaging, digital solutions, and artificial intelligence
- Reinforcement of the Executive Committee
- 2020 objectives: EBITDA margin around 14%
- Second-half revenue comparable with the first half, leading to a decrease of approximately 10% over the year at CER
- Long-term reduction of structural costs, improving operational leverage
- Acceleration of the transformation
Villepinte, September 23, 2020 – Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, announced its consolidated results for the first half of 2020.
On the occasion of this publication, David Hale, Chief Executive Officer of Guerbet, stated: “Together we’ve shown agility and exemplary resilience during this unusual period. In that respect, I’d like to give warm thanks to all our staff. We’ve also implemented strict budgetary discipline to return to our path to sustainable development. During this period, we continued the roadmap on our promising projects: continued R&D, digitization, and an active search for acquisitions in Interventional Imaging. With a portfolio of quality products in growing markets, a reinforced Executive Committee, and a solid financial structure, all the pieces are there to speed up our profitable growth once business will be back to normal”.
Europe and the Americas impacted by the health crisis, good sales in Asia
The health crisis had a major impact on the first half of the year. Since the crisis began, Guerbet has taken swift action to ensure employee safety and business continuity. All of the Group’s production plants and logistics centers around the world continued to operate.
The postponement of non-essential radiological examinations and procedures by radiologists, combined with spontaneous cancellations by certain patients and the increase in longer disinfection and protection measures due to SARS-Cov-2, impacted activity, especially MRI but also CT/Cath Lab.
The development of artificial intelligence solutions and digital solutions continued without any impact on project progress or on their actual market release date. Regarding Gadopiclenol, the recruitment of phase IIIb patients was logically slowed down during the lockdown, delaying the process in progress accordingly. The market release is still planned for the first part of 2023.
Revenue was €363.7 million at June 30, down 9.2% compared with the first half of 2019, including an unfavorable forex impact of €3.4 million (€367.1 at constant exchange rates). This decrease at constant exchange rates was driven by sales drop of 21.2% in Europe and 13.6% in the Americas. In Asia, the implementation of Go-Direct in Japan and good sales in China led to 9% increase.
Diagnostic Imaging revenue was €308.4 million, compared with €354.6 million in the first half of 2019, down 13.0% (-11.9% at CER). The main reason was the impact of the health crisis following the lockdown in most countries.
- MRI sales decreased 18.7% (identical at constant exchange rates) to €110.9 million;
- CT/Cath Lab revenue was down 9.7% at €196.0 million with reduced volumes across all products in the range except for Xenetix® used in some countries for the diagnostic of the most serious Covid cases (At CER, revenue for the half-year period was €199.9 million, down -7.9%).
Interventional Imaging continued to be driven by Lipiodol® sales. Its revenue totaled €36 million, up 3.1% (+1.9% at CER) from €34.9 million in the same period last year.
Satisfactory results under unprecedented health conditions
In millions of euros
Consolidated financial statements (IFRS) |
H1 2019 | H1 2020 |
Revenue | 400.6 | 363.7 |
EBITDA (2) | 61.6 | 53.3 |
% of revenue | 15.4% | 14.7% |
Operating income | 22.3 | 25.4 |
% of revenue | 5.6% | 7.0% |
Net income | 19.0 | 8.2 |
% of revenue | 4.8% | 2.3% |
Net Debt | 358.1 | 269.3 |
The financial statements for the first half of 2020, approved by the Board of Directors on 23 September 2020, underwent a limited review by the statutory auditors. The statutory auditors’ report is currently being drawn up.
EBITDA stood at €53.3 million compared with €61.6 million in the first half of 2019. However, it represents 14.7% of revenue for the period, which was a satisfactory performance for the Group given the significant drop in activity.
The EBITDA margin rate was maintained thanks to strict budgetary discipline. It concerned sales and marketing costs and the acceleration of the “Cost to Win” plan. The total reduction of expenditures over the first half of the year was around €20 million.
As of June 30, 2020, operating income totaled €25.4 million and represented 7.0% of revenue. Net income was €8.2 million compared with €19.0 million at June 30, 2019. This decrease between the two periods is primarily explained by significant favorable forex gains in 2019 as well as the write-down of the Canadian subsidiary’s assets in June 2020 for €5.7 million in anticipation of the sale of the Montreal production plant on July 15, 2020, associated with the agreed sale price.
Sound financial structure
As of June 30, 2020, shareholders’ equity amounted to €374.9 million compared with €367.9 million for the same period last year. The Group has reduced its debt dramatically. At the end of June, the net debt/EBITDA ratio was 2.61 compared with 3.06 at June 30, 2019. This improvement brought net debt to €269.3 million at June 30, 2020, compared with €358.1 million at the end of the first half of 2019.
Stronger governance
To accelerate its transformation and achieve its strategic ambitions, the Group recently announced the reinforcement of its Executive Committee with four new functions dedicated to Diagnostic Imaging and Interventional Imaging franchises and its Asia-Pacific, Americas, and EMEA regions.
2020 outlook
The future of the health situation remains uncertain, and the gradual upturn in activity is still inconsistent. July benefited from a restocking effect, but activity fell in August.
In the coming months, the Group’s activity is expected to be affected by the initial sales of the generic of Dotarem® in the United States. The Group believes that the change in Dotarem® volumes and prices should be comparable with Europe, where the generic has already been available for more than two years. Moreover, Guerbet should continue to benefit from the good performance of Lipiodol® and the strength of Xenetix® and Optiray®.
Given the impact of the generic and against the backdrop of a stabilized health crisis with normal operation of the healthcare system, the Group expects second-half revenue to be largely comparable with the first-half revenue, down 12% compared with 2019 at constant exchange rates. On this basis, the Group expects EBITDA for the 2020 financial year to be around 14% of revenue.
Lastly, the Group is confident that it can lower its level of structural costs for the long term with expectations of a very favorable impact on profitability once business is back to normal.
(1) At constant exchange rates: amounts and rates of growth are calculated by canceling out the exchange rate effect, which is defined as the difference between the indicator’s value for period N, converted at the exchange rate for period N-1, and the indicator’s value for period N-1.
(2) EBITDA refers to operating income with the net allowance for amortization, depreciation, and provisions added back in.
Upcoming events:
Publication of revenue at September 30, 2020
October 22, 2020, after trading
About Guerbet
Guerbet is a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging to improve patient diagnosis and treatment. A pioneer in contrast media for more than 90 years, with more than 2,800 employees worldwide, Guerbet continuously innovates and devotes 9% of its sales to research and development in four centers in France, Israel, and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €817 million in revenue in 2019. For more information about Guerbet, please visit www.guerbet.com
Forward-looking statements
Certain information contained in this press release does not reflect historical data but constitutes forward-looking statements. These forward-looking statements are based on estimates, forecasts, and assumptions, including but not limited to assumptions about the current and future strategy of the Group and the economic environment in which the Group operates. They involve known and unknown risks, uncertainties, and other factors that may result in a significant difference between the Group’s actual performance and results and those presented explicitly or implicitly by these forward-looking statements.
These forward-looking statements are valid only as of the date of this press release, and the Group expressly disclaims any obligation or commitment to publish an update or revision of the forward-looking statements contained in this press release to reflect changes in their underlying assumptions, events, conditions, or circumstances. The forward-looking statements contained in this press release are for illustrative purposes only. Forward-looking statements and information are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and are generally beyond the Group’s control. These risks and uncertainties include but are not limited to the uncertainties inherent in research and development, future clinical data and analyses (including after a marketing authorization is granted), decisions by regulatory authorities (such as the US Food and Drug Administration or the European Medicines Agency) regarding whether and when to approve any application for a drug, process, or biological product filed for any such product candidates, as well as their decisions regarding labeling and other factors that may affect the availability or commercial potential of such product candidates. A detailed description of the risks and uncertainties related to the Group’s activities can be found in Chapter 4.8 “Risk management and risk factors” of the Group’s Universal Registration Document filed with the French Financial Markets Authority (AMF) under number D-20-0369 on April 28, 2020, available on the Group’s website (www.guerbet.com).
For more information about Guerbet, please visit www.guerbet.com
Contacts
Guerbet | Actifin |
Jérôme Estampes Chief Financial Officer +33 (0)1 45 91 50 00
|
Financial Communications Benjamin Lehari +33 (0)1 56 88 11 25 [email protected]
Press |
Attachment
Artificial Intelligence
University medical centers in Germany choose Sectra’s radiology solution to streamline workflows and shorten lead times for patients
LINKÖPING, Sweden, April 23, 2024 /PRNewswire/ — International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed two contracts to provide the radiology module of its enterprise imaging solution with two university medical centers in Germany—Universitätsklinikum Tübingen and Universitätsmedizin Göttingen. By implementing Sectra’s radiology solution, the hospitals aim to improve and streamline radiology workflows with Sectra’s tools for enhanced reporting efficiency, in turn speeding up diagnostics.
“When choosing a vendor, we wanted one that could provide us with a stable and fast system. We also wanted one facilitating collaboration among our radiologists. That way we can streamline our radiology workflows and in turn shorten lead times for patients as well as reduce the ever increasing workload for radiologists,” says Dr. Babak Panahi, Managing Senior Physician and Head of CT and CT Intervention, Universitätsmedizin Göttingen.
Universitätsmedizin Göttingen and Universitätsklinikum Tübingen are two university medical centers located in the cities of Göttingen and Tübingen in Germany managing 300,000 and 600,000 radiology exams a year. The two separate contracts for Sectra’s radiology solution were both signed during the third quarter of Sectra’s 2023/2024 fiscal year.
“Radiologists are under a lot of pressure as they are challenged to handle more images and more complex cases with less resources. Having a solution designed to streamline radiology workflows, facilitating reading and reporting of images, is therefore paramount. I am happy and excited to support Universitätsmedizin Göttingen and Universitätsklinikum Tübingen on their journey towards efficient radiology diagnostics,” says Guido Bötticher, Managing Director, Sectra DACH.
The radiology module is part of Sectra’s enterprise imaging solution that provides a unified strategy for all imaging needs while lowering operational costs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise. Visit Sectra’s website to read more about Sectra and why it’s top-ranked in ‘Best in KLAS’.
About SectraSectra contributes to a healthier and safer society by assisting health systems throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society’s most sensitive information. The company, founded in 1978, is headquartered in Linköping, Sweden, with direct sales in 19 countries, and distribution partners worldwide. Sales in the 2022/2023 fiscal year totaled SEK 2,351 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit Sectra’s website.
For further information, please contact: Dr. Torbjörn Kronander, CEO and President Sectra AB, 46 (0) 705 23 52 27Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, 46 (0)708 23 56 10
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/sectra/r/university-medical-centers-in-germany-choose-sectra-s-radiology-solution-to-streamline-workflows-and,c3965089
The following files are available for download:
https://news.cision.com/sectra/i/sectra-s-radiology-solution,c3291783
Sectra’s radiology solution
View original content:https://www.prnewswire.co.uk/news-releases/university-medical-centers-in-germany-choose-sectras-radiology-solution-to-streamline-workflows-and-shorten-lead-times-for-patients-302124211.html
Artificial Intelligence
New CPS Protection Platform: TXOne Networks Unveils SageOne at GISec Global
TAIPEI, April 23, 2024 /PRNewswire/ — TXOne Networks, a frontrunner in the realm of cyber-physical systems (CPS) security, is set to unveil its groundbreaking CPS security platform, SageOne, at the highly anticipated GISec Global from April 23rd to 25th, 2024. Attendees can find TXOne Networks showcasing SageOne at stand B99 in hall 5. This innovative platform consolidates all CPS security products onto a single, central management platform, promising streamlined operations and optimized threat detection capabilities.
SageOne, aptly named “Wise Man Number One,” serves as a comprehensive management console providing a holistic view of the CPS attack surface within operational technology (OT) environments. By enabling centralized control of TXOne’s three core product lines – Stellar for endpoint protection, Element for security inspection, and Edge for network defense – SageOne facilitates integrated OT security throughout the lifecycle of protected assets, ensuring robust threat detection and response mechanisms.
Key features of SageOne include:
CPS Attack Surface Management: Prioritizing operational security by offering clear visibility into the overall security posture of OT environments, SageOne identifies security focal points, illuminating asset information and security controls.Integrated Lifecycle Protection: Through centralized management, SageOne simplifies cybersecurity governance and fosters collaborative defense. It serves as an abstraction layer, facilitating contextualization and consolidation of data across multiple products, offering tailored, task-oriented consoles for executives, security personnel, and plant leaders.CPS Threat Detection & Response: SageOne aggregates security insights from various solutions to scout for potential risks, enabling early caution and response to both known and unknown threats.SageOne’s foundation rests upon advanced components, including Threat Intelligence, Behavior-Based AI Analytics Engines, Compliance Framework, Data Visualizer, and Ecosystem Integrator, ensuring comprehensive protection and seamless integration of different tools and technologies.
With its focus on analyzing unexpected behavior and unknown threats, SageOne enables the identification of suspicious events through cross-telemetry analysis within the OT-native XDR engine. This amalgamation of advanced technologies and user-friendly interface ensures the protection of critical infrastructures.
For rapid threat response, SageOne issues early warnings of suspicious behavior and orchestrates cross-telemetry analysis for CPS Threat Detection & Response. Integrated Lifecycle Protection ensures the security of devices and systems throughout their service life, contributing to great cost efficiency.
TXOne Networks reaffirms its commitment to CPS security and continuous advancement in OT security through SageOne. Visit TXOne Networks at the GISec Global from April 23rd to 25th, 2024, at stand B99 in hall 5.
For further updates and information, follow TXOne Networks on the blog, Twitter, and LinkedIn.
About TXOne Networks:
TXOne Networks provides OT security products ensuring reliability and security in industrial control systems and operational technology environments through the OT Zero Trust methodology. Collaborating with leading industrial manufacturers and critical infrastructure operators, TXOne Networks offers practical and business-friendly approaches to OT defense. Its network and endpoint-based products secure OT networks and mission-critical devices in real-time with high security depth.
Website: www.txone.com
Photo – https://mma.prnewswire.com/media/2389611/SageOne_header_3.jpg
View original content:https://www.prnewswire.co.uk/news-releases/new-cps-protection-platform-txone-networks-unveils-sageone-at-gisec-global-302119386.html
Artificial Intelligence
Imparta Launches World’s First Sales Methodology-Aware AI
LONDON, April 23, 2024 /PRNewswire/ — Imparta Ltd, a global leader in performance improvement for customer-facing teams, has announced the release of i-Coach AI, the world’s first sales methodology-aware AI.
Over the past 18 months, AI has reshaped many industries and professions, with sales being no exception. Yet, generic LLMs such as ChatGPT are poor at coaching, and at selling. Even data-driven AI insights are only as good as the qualitative frameworks that underpin their observations.
i-Coach AI is the first expert Sales AI Coach that follows a proven, structured coaching process, and is fluent in all aspects of sales, account management, negotiation, customer success, commercial and business acumen, sales management and sales leadership. It is powered by Imparta’s award-winning, research-based Agile 3D methodology and complete, modular skills library.
Richard Barkey, Founder and CEO of Imparta, said “GenAI is one of the few truly transformative technologies in our lifetimes, and one that no sales organisation can ignore. We are genuinely excited to introduce i-Coach AI, an enterprise-grade coaching tool for salespeople, managers and leaders. I’m not exaggerating when I say that I’m using i-Coach AI myself, to think through strategies around specific clients, and indeed for the whole business. This tool is designed to integrate seamlessly across various sales ecosystems and tech stacks, and provides targeted, IP-aware coaching and practice simulations of customer conversations, at multiple points of need.”
As part of the launch, Imparta will host a webinar on April 23rd and May 2nd, hosted by Richard Barkey, titled ‘Leveraging Sales Methodology-Aware AI at Scale in the Enterprise’. Click here to learn more.
During this webinar, Richard will announce details of i-Coach AI and Imparta’s upcoming course for sales teams: Leveraging AI for Sales. He will also set out a range of essential use cases that we are rolling out across Imparta’s agile sales ecosystem and across the tech stack.
About Imparta
Imparta is a global leader in performance improvement for Sales, CX and Leadership. Our modular ecosystem includes three elements, developed through 25 years of research and experience with leading global organisations: Agile Sales Methodology, Agile Change Process and AI Sales Technology.
Whether you need to plug a gap in your existing training, provide self-paced learning, or build an entire Sales, CX or Leadership Academy, get in touch at [email protected].
Website: www.imparta.com
Photo: https://mma.prnewswire.com/media/2392278/i_Coach_Imparta_Ltd.jpg
Contact details: Adam [email protected] Tel: +44 (0) 20 7610 8800
View original content:https://www.prnewswire.co.uk/news-releases/imparta-launches-worlds-first-sales-methodology-aware-ai-302123771.html
-
Artificial Intelligence6 days ago
Huawei Introduces AI Technologies to Accelerate Network Transformation Towards All Intelligence in the Net5.5G Era
-
Uncategorized4 days ago
Generative AI gold rush drives IT spending — with payoff in question
-
Uncategorized4 days ago
Do underwriters trust artificial intelligence?
-
Uncategorized4 days ago
Hans Jonas on Responsibility in the Age of Artificial Intelligence
-
Uncategorized4 days ago
Meta AI Assistant Adds Website, Expands Beyond US
-
Uncategorized4 days ago
Can artificial intelligence reduce vehicle time to market?
-
Uncategorized4 days ago
The Ottawa Hospital doctors to try AI for patient notes
-
Artificial Intelligence7 days ago
SQream’s No-Code Platform Panoply Earns 21 G2 Badges in Key Customer Satisfaction Categories for Spring 2024 Report